| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anti-Bacterial Agents | 50 | 2021 | 10083 | 4.56 | Why? |
| Skin Diseases, Bacterial | 9 | 2021 | 105 | 3.41 | Why? |
| Pseudomonas aeruginosa | 12 | 2020 | 652 | 3.13 | Why? |
| Pseudomonas Infections | 10 | 2020 | 425 | 3.05 | Why? |
| Soft Tissue Infections | 6 | 2018 | 116 | 2.78 | Why? |
| Cephalosporins | 9 | 2018 | 250 | 2.61 | Why? |
| Bacteremia | 14 | 2020 | 1372 | 2.58 | Why? |
| Drug Resistance, Multiple, Bacterial | 20 | 2019 | 1115 | 2.53 | Why? |
| Candidemia | 7 | 2020 | 353 | 2.36 | Why? |
| Gram-Negative Bacterial Infections | 7 | 2018 | 398 | 2.07 | Why? |
| Klebsiella Infections | 8 | 2018 | 466 | 2.04 | Why? |
| Antifungal Agents | 12 | 2020 | 1828 | 1.99 | Why? |
| beta-Lactamase Inhibitors | 3 | 2018 | 104 | 1.94 | Why? |
| Gram-Negative Bacteria | 8 | 2018 | 473 | 1.93 | Why? |
| Antimicrobial Stewardship | 7 | 2020 | 931 | 1.92 | Why? |
| Klebsiella pneumoniae | 9 | 2018 | 658 | 1.87 | Why? |
| Skin Diseases, Infectious | 3 | 2018 | 77 | 1.78 | Why? |
| Gram-Positive Bacterial Infections | 7 | 2021 | 323 | 1.64 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 7 | 2019 | 711 | 1.64 | Why? |
| Drug Resistance, Bacterial | 8 | 2019 | 1414 | 1.58 | Why? |
| Staphylococcal Infections | 6 | 2020 | 1099 | 1.37 | Why? |
| Enterobacteriaceae Infections | 6 | 2020 | 529 | 1.31 | Why? |
| Pneumonia, Ventilator-Associated | 7 | 2019 | 861 | 1.29 | Why? |
| Candidiasis | 4 | 2018 | 334 | 1.29 | Why? |
| Fluoroquinolones | 2 | 2018 | 235 | 1.26 | Why? |
| Invasive Fungal Infections | 4 | 2019 | 274 | 1.21 | Why? |
| Bacterial Infections | 8 | 2019 | 2229 | 1.13 | Why? |
| Candida | 7 | 2018 | 425 | 1.07 | Why? |
| Penicillanic Acid | 3 | 2018 | 58 | 1.04 | Why? |
| Thienamycins | 3 | 2018 | 72 | 1.00 | Why? |
| Carbapenems | 4 | 2019 | 343 | 1.00 | Why? |
| Aspergillosis | 2 | 2017 | 264 | 0.93 | Why? |
| Mycoses | 3 | 2018 | 589 | 0.92 | Why? |
| beta-Lactam Resistance | 3 | 2019 | 150 | 0.91 | Why? |
| Anti-Inflammatory Agents | 4 | 2020 | 6153 | 0.87 | Why? |
| Fluorodeoxyglucose F18 | 3 | 2017 | 1153 | 0.87 | Why? |
| Intraabdominal Infections | 4 | 2018 | 90 | 0.87 | Why? |
| Intensive Care Units | 22 | 2021 | 29594 | 0.85 | Why? |
| Diet, Carbohydrate-Restricted | 1 | 2020 | 36 | 0.84 | Why? |
| Ketosis | 1 | 2020 | 44 | 0.83 | Why? |
| Teicoplanin | 2 | 2021 | 191 | 0.80 | Why? |
| Drug Monitoring | 6 | 2019 | 1408 | 0.80 | Why? |
| Shock, Septic | 3 | 2018 | 1313 | 0.78 | Why? |
| Methylprednisolone | 2 | 2020 | 2107 | 0.77 | Why? |
| Superinfection | 2 | 2020 | 459 | 0.74 | Why? |
| Staphylococcal Skin Infections | 2 | 2017 | 32 | 0.72 | Why? |
| Acinetobacter baumannii | 2 | 2019 | 378 | 0.72 | Why? |
| Enterobacteriaceae | 3 | 2018 | 395 | 0.71 | Why? |
| beta-Lactamases | 4 | 2018 | 759 | 0.71 | Why? |
| Critical Illness | 18 | 2021 | 17281 | 0.71 | Why? |
| Biomedical Engineering | 1 | 2018 | 91 | 0.69 | Why? |
| Candidiasis, Invasive | 2 | 2018 | 107 | 0.68 | Why? |
| Discitis | 1 | 2017 | 23 | 0.68 | Why? |
| Herpes Zoster Vaccine | 1 | 2019 | 112 | 0.67 | Why? |
| Cross Infection | 12 | 2020 | 8675 | 0.67 | Why? |
| Ganciclovir | 1 | 2017 | 97 | 0.66 | Why? |
| Neuraminidase | 1 | 2019 | 289 | 0.66 | Why? |
| Prosthesis-Related Infections | 2 | 2017 | 302 | 0.65 | Why? |
| Off-Label Use | 3 | 2020 | 553 | 0.65 | Why? |
| Roseolovirus Infections | 1 | 2017 | 131 | 0.62 | Why? |
| Blood Culture | 1 | 2018 | 308 | 0.62 | Why? |
| Lung Diseases, Fungal | 1 | 2017 | 167 | 0.60 | Why? |
| Drug Therapy | 1 | 2018 | 280 | 0.58 | Why? |
| Radiopharmaceuticals | 2 | 2017 | 763 | 0.57 | Why? |
| Microbial Sensitivity Tests | 11 | 2018 | 2886 | 0.57 | Why? |
| Drug Substitution | 1 | 2018 | 385 | 0.55 | Why? |
| Bacterial Proteins | 3 | 2018 | 1318 | 0.55 | Why? |
| Invasive Pulmonary Aspergillosis | 2 | 2021 | 634 | 0.52 | Why? |
| Immunoconjugates | 1 | 2013 | 90 | 0.52 | Why? |
| Herpes Zoster | 1 | 2019 | 331 | 0.51 | Why? |
| Humans | 127 | 2021 | 930598 | 0.51 | Why? |
| Terminology as Topic | 1 | 2019 | 546 | 0.51 | Why? |
| Immunocompromised Host | 4 | 2021 | 5150 | 0.50 | Why? |
| Opportunistic Infections | 2 | 2017 | 602 | 0.50 | Why? |
| Encephalitis, Viral | 1 | 2017 | 355 | 0.50 | Why? |
| Standard of Care | 2 | 2017 | 1297 | 0.50 | Why? |
| Positron Emission Tomography Computed Tomography | 3 | 2017 | 1458 | 0.49 | Why? |
| Bronchoalveolar Lavage Fluid | 2 | 2021 | 2309 | 0.49 | Why? |
| Pneumonia, Pneumocystis | 1 | 2017 | 322 | 0.49 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 4 | 2018 | 214 | 0.48 | Why? |
| Echinocandins | 3 | 2018 | 139 | 0.47 | Why? |
| Administration, Intravenous | 5 | 2019 | 1115 | 0.47 | Why? |
| Macrophages | 2 | 2021 | 2784 | 0.45 | Why? |
| Positron-Emission Tomography | 1 | 2017 | 802 | 0.45 | Why? |
| Peritonitis | 1 | 2013 | 217 | 0.45 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.44 | Why? |
| Pulmonary Aspergillosis | 3 | 2021 | 408 | 0.44 | Why? |
| Italy | 27 | 2021 | 38444 | 0.44 | Why? |
| Leukocyte Count | 1 | 2021 | 3178 | 0.43 | Why? |
| Hodgkin Disease | 1 | 2013 | 204 | 0.43 | Why? |
| Aspergillus | 3 | 2020 | 347 | 0.43 | Why? |
| Anti-Infective Agents | 5 | 2018 | 1766 | 0.42 | Why? |
| Herpesvirus 1, Human | 1 | 2013 | 286 | 0.42 | Why? |
| Antiviral Agents | 7 | 2021 | 41703 | 0.42 | Why? |
| Nebulizers and Vaporizers | 4 | 2018 | 497 | 0.41 | Why? |
| Herpes Simplex | 1 | 2013 | 272 | 0.41 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 9335 | 0.41 | Why? |
| Pneumonia, Bacterial | 5 | 2019 | 843 | 0.41 | Why? |
| Treatment Outcome | 20 | 2021 | 51732 | 0.40 | Why? |
| Hyperglycemia | 1 | 2020 | 1363 | 0.39 | Why? |
| Heart-Assist Devices | 1 | 2017 | 812 | 0.38 | Why? |
| Fluconazole | 3 | 2018 | 145 | 0.37 | Why? |
| Professional Role | 1 | 2018 | 1280 | 0.37 | Why? |
| Decontamination | 1 | 2018 | 1196 | 0.37 | Why? |
| Respiration, Artificial | 9 | 2021 | 22116 | 0.37 | Why? |
| Linezolid | 2 | 2019 | 160 | 0.36 | Why? |
| Enzyme Inhibitors | 1 | 2019 | 1881 | 0.36 | Why? |
| Pharmacists | 1 | 2018 | 1246 | 0.34 | Why? |
| Mucormycosis | 1 | 2017 | 832 | 0.34 | Why? |
| Heart Transplantation | 1 | 2017 | 1293 | 0.33 | Why? |
| Heart Valve Diseases | 2 | 2017 | 355 | 0.33 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.32 | Why? |
| Influenza, Human | 3 | 2020 | 10779 | 0.32 | Why? |
| Endocarditis, Bacterial | 2 | 2018 | 344 | 0.32 | Why? |
| Carrier State | 1 | 2018 | 2100 | 0.31 | Why? |
| Infection Control | 4 | 2021 | 23131 | 0.31 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.31 | Why? |
| Male | 51 | 2021 | 367725 | 0.30 | Why? |
| Middle Aged | 44 | 2021 | 270681 | 0.30 | Why? |
| Drug Design | 1 | 2018 | 2627 | 0.30 | Why? |
| Streptococcus bovis | 1 | 2004 | 1 | 0.30 | Why? |
| Immunity, Cellular | 1 | 2019 | 3614 | 0.30 | Why? |
| Pneumonia, Viral | 17 | 2021 | 243684 | 0.29 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.29 | Why? |
| Triazoles | 3 | 2020 | 440 | 0.29 | Why? |
| Streptococcus pneumoniae | 2 | 2020 | 827 | 0.29 | Why? |
| Drug Therapy, Combination | 6 | 2018 | 7268 | 0.29 | Why? |
| Aged | 35 | 2021 | 215776 | 0.28 | Why? |
| Hydroxychloroquine | 4 | 2021 | 12447 | 0.28 | Why? |
| Biofilms | 2 | 2017 | 304 | 0.28 | Why? |
| Nitriles | 3 | 2020 | 1053 | 0.27 | Why? |
| Female | 45 | 2021 | 380317 | 0.27 | Why? |
| Staphylococcus aureus | 3 | 2020 | 844 | 0.27 | Why? |
| Feces | 2 | 2016 | 4235 | 0.26 | Why? |
| Pyridines | 3 | 2020 | 680 | 0.26 | Why? |
| Coronavirus Infections | 15 | 2020 | 253789 | 0.25 | Why? |
| Gram-Positive Bacteria | 2 | 2017 | 230 | 0.25 | Why? |
| Disease Management | 4 | 2019 | 6841 | 0.24 | Why? |
| Pneumonia | 4 | 2018 | 5652 | 0.24 | Why? |
| Forecasting | 1 | 2017 | 4492 | 0.24 | Why? |
| Risk Factors | 16 | 2020 | 71621 | 0.24 | Why? |
| Drug Administration Schedule | 3 | 2021 | 2324 | 0.24 | Why? |
| Retrospective Studies | 22 | 2021 | 105322 | 0.24 | Why? |
| Pancreas Transplantation | 1 | 2004 | 163 | 0.23 | Why? |
| C-Reactive Protein | 1 | 2018 | 7972 | 0.23 | Why? |
| Endocarditis | 2 | 2017 | 368 | 0.23 | Why? |
| Renal Dialysis | 1 | 2019 | 4358 | 0.23 | Why? |
| Enterobacter aerogenes | 1 | 2020 | 24 | 0.22 | Why? |
| Skin | 1 | 2013 | 2096 | 0.22 | Why? |
| Leukocidins | 2 | 2018 | 47 | 0.22 | Why? |
| Critical Care | 4 | 2020 | 14081 | 0.22 | Why? |
| T-Lymphocytes | 1 | 2019 | 6670 | 0.22 | Why? |
| Administration, Oral | 2 | 2019 | 2340 | 0.22 | Why? |
| Exotoxins | 2 | 2018 | 54 | 0.22 | Why? |
| Streptococcal Infections | 1 | 2004 | 255 | 0.22 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.22 | Why? |
| Blood Volume | 1 | 2021 | 90 | 0.22 | Why? |
| Tuberculosis | 1 | 2017 | 2895 | 0.21 | Why? |
| Galactose | 2 | 2020 | 201 | 0.21 | Why? |
| Double-Blind Method | 3 | 2021 | 5988 | 0.21 | Why? |
| Vinyl Compounds | 1 | 2019 | 24 | 0.21 | Why? |
| Enterococcus faecalis | 1 | 2020 | 126 | 0.20 | Why? |
| Enterococcus faecium | 1 | 2020 | 95 | 0.20 | Why? |
| Mannans | 2 | 2020 | 218 | 0.20 | Why? |
| Urinary Tract Infections | 4 | 2018 | 534 | 0.20 | Why? |
| Zanamivir | 1 | 2019 | 63 | 0.20 | Why? |
| Glycolysis | 1 | 2020 | 208 | 0.20 | Why? |
| Bone Diseases, Infectious | 1 | 2018 | 20 | 0.19 | Why? |
| Bacterial Toxins | 2 | 2018 | 185 | 0.19 | Why? |
| Voriconazole | 2 | 2020 | 206 | 0.19 | Why? |
| Minocycline | 2 | 2017 | 101 | 0.19 | Why? |
| Klebsiella | 1 | 2018 | 35 | 0.19 | Why? |
| Ketones | 1 | 2020 | 150 | 0.19 | Why? |
| Glycopeptides | 2 | 2018 | 199 | 0.19 | Why? |
| Receptors, Urokinase Plasminogen Activator | 1 | 2021 | 252 | 0.19 | Why? |
| Tetracyclines | 1 | 2019 | 82 | 0.19 | Why? |
| Half-Life | 1 | 2019 | 298 | 0.18 | Why? |
| Pulmonary Gas Exchange | 1 | 2021 | 414 | 0.18 | Why? |
| Aged, 80 and over | 14 | 2021 | 88759 | 0.18 | Why? |
| Vaccines, Conjugate | 1 | 2020 | 328 | 0.18 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.18 | Why? |
| Cohort Studies | 9 | 2021 | 36005 | 0.18 | Why? |
| Mucor | 1 | 2017 | 13 | 0.17 | Why? |
| Energy Intake | 1 | 2020 | 323 | 0.17 | Why? |
| Global Health | 3 | 2017 | 13911 | 0.17 | Why? |
| Candida parapsilosis | 1 | 2017 | 34 | 0.17 | Why? |
| HIV Infections | 3 | 2020 | 11620 | 0.17 | Why? |
| Azabicyclo Compounds | 1 | 2018 | 91 | 0.17 | Why? |
| Intervertebral Disc | 1 | 2017 | 16 | 0.17 | Why? |
| Cerebrovascular Circulation | 1 | 2021 | 340 | 0.17 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.17 | Why? |
| Colistin | 2 | 2017 | 217 | 0.17 | Why? |
| Fasciitis, Necrotizing | 1 | 2018 | 56 | 0.17 | Why? |
| Praziquantel | 1 | 2017 | 44 | 0.17 | Why? |
| Antibodies, Fungal | 1 | 2017 | 49 | 0.17 | Why? |
| Ceftazidime | 1 | 2018 | 134 | 0.17 | Why? |
| Lactic Acid | 1 | 2020 | 393 | 0.17 | Why? |
| Phage Therapy | 1 | 2017 | 63 | 0.17 | Why? |
| Adrenal Cortex Hormones | 1 | 2014 | 6537 | 0.16 | Why? |
| Drug Resistance, Multiple | 1 | 2017 | 156 | 0.16 | Why? |
| Darunavir | 1 | 2020 | 477 | 0.16 | Why? |
| Antibodies, Helminth | 1 | 2016 | 48 | 0.16 | Why? |
| Schistosomiasis haematobia | 1 | 2017 | 45 | 0.16 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 3832 | 0.16 | Why? |
| HIV Protease Inhibitors | 1 | 2020 | 434 | 0.16 | Why? |
| Hemofiltration | 1 | 2018 | 155 | 0.16 | Why? |
| Antibodies, Bacterial | 1 | 2020 | 510 | 0.16 | Why? |
| Pyrroles | 1 | 2019 | 292 | 0.16 | Why? |
| Drug Resistance, Fungal | 1 | 2018 | 191 | 0.15 | Why? |
| Microvessels | 1 | 2020 | 490 | 0.15 | Why? |
| Acinetobacter Infections | 1 | 2019 | 273 | 0.15 | Why? |
| Infusions, Intravenous | 2 | 2017 | 1224 | 0.15 | Why? |
| Retina | 1 | 2020 | 424 | 0.15 | Why? |
| Pulmonary Alveoli | 1 | 2021 | 867 | 0.15 | Why? |
| Strongyloides stercoralis | 1 | 2016 | 70 | 0.15 | Why? |
| Herpesvirus 6, Human | 1 | 2017 | 162 | 0.15 | Why? |
| Biomarkers | 5 | 2018 | 23361 | 0.15 | Why? |
| Betacoronavirus | 14 | 2020 | 204454 | 0.15 | Why? |
| Strongyloidiasis | 1 | 2016 | 80 | 0.15 | Why? |
| Age Factors | 5 | 2020 | 21039 | 0.14 | Why? |
| Oseltamivir | 1 | 2019 | 583 | 0.14 | Why? |
| beta-Glucans | 1 | 2017 | 176 | 0.14 | Why? |
| Bacteriological Techniques | 1 | 2017 | 239 | 0.14 | Why? |
| Pneumococcal Vaccines | 1 | 2020 | 571 | 0.14 | Why? |
| Escherichia coli Infections | 1 | 2018 | 348 | 0.14 | Why? |
| Heart Conduction System | 1 | 2018 | 266 | 0.14 | Why? |
| Multivariate Analysis | 4 | 2019 | 5440 | 0.14 | Why? |
| Adult | 24 | 2021 | 244371 | 0.14 | Why? |
| Tissue Plasminogen Activator | 1 | 2021 | 778 | 0.14 | Why? |
| Community-Acquired Infections | 3 | 2017 | 2328 | 0.14 | Why? |
| Salvage Therapy | 1 | 2017 | 417 | 0.14 | Why? |
| Hydrogen-Ion Concentration | 1 | 2018 | 993 | 0.14 | Why? |
| Area Under Curve | 2 | 2018 | 2564 | 0.14 | Why? |
| Neutrophils | 2 | 2021 | 5476 | 0.13 | Why? |
| Pneumococcal Infections | 1 | 2020 | 562 | 0.13 | Why? |
| Expert Testimony | 1 | 2018 | 658 | 0.13 | Why? |
| Drug Utilization | 1 | 2019 | 619 | 0.13 | Why? |
| Time Factors | 6 | 2018 | 31397 | 0.13 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2021 | 1165 | 0.12 | Why? |
| Incidence | 4 | 2020 | 25622 | 0.12 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 3 | 2019 | 1261 | 0.12 | Why? |
| Respiratory Tract Infections | 4 | 2018 | 6817 | 0.12 | Why? |
| Communicable Diseases | 2 | 2018 | 2148 | 0.12 | Why? |
| Drug Resistance, Viral | 1 | 2019 | 1083 | 0.12 | Why? |
| Positive-Pressure Respiration | 1 | 2021 | 1160 | 0.12 | Why? |
| Data Accuracy | 1 | 2018 | 715 | 0.12 | Why? |
| Case-Control Studies | 4 | 2021 | 17671 | 0.12 | Why? |
| Sepsis | 3 | 2018 | 3517 | 0.12 | Why? |
| Prospective Studies | 8 | 2021 | 43301 | 0.11 | Why? |
| Lymphohistiocytosis, Hemophagocytic | 1 | 2020 | 800 | 0.11 | Why? |
| Consensus | 4 | 2019 | 6345 | 0.11 | Why? |
| HIV | 1 | 2019 | 1116 | 0.11 | Why? |
| Drug Combinations | 2 | 2018 | 3852 | 0.11 | Why? |
| Physical Therapy Modalities | 1 | 2020 | 1090 | 0.11 | Why? |
| Disseminated Intravascular Coagulation | 1 | 2020 | 994 | 0.11 | Why? |
| Administration, Inhalation | 1 | 2018 | 1647 | 0.11 | Why? |
| Antimalarials | 2 | 2020 | 2505 | 0.11 | Why? |
| Heart Valve Prosthesis | 1 | 2017 | 533 | 0.11 | Why? |
| Pulmonary Embolism | 2 | 2021 | 4775 | 0.11 | Why? |
| Killer Cells, Natural | 1 | 2021 | 2093 | 0.11 | Why? |
| Prevalence | 6 | 2020 | 25773 | 0.11 | Why? |
| Proportional Hazards Models | 2 | 2020 | 6543 | 0.11 | Why? |
| Comorbidity | 4 | 2020 | 34796 | 0.10 | Why? |
| Practice Guidelines as Topic | 4 | 2018 | 15421 | 0.10 | Why? |
| Safety | 1 | 2018 | 1583 | 0.10 | Why? |
| Prognosis | 3 | 2020 | 32490 | 0.10 | Why? |
| Renal Insufficiency | 1 | 2017 | 810 | 0.10 | Why? |
| Acute Disease | 2 | 2021 | 6029 | 0.10 | Why? |
| Pandemics | 19 | 2020 | 389249 | 0.10 | Why? |
| Perception | 1 | 2020 | 2827 | 0.10 | Why? |
| Organ Transplantation | 1 | 2004 | 2616 | 0.10 | Why? |
| Fibrinolytic Agents | 1 | 2021 | 1702 | 0.10 | Why? |
| Blood Platelets | 1 | 2020 | 1704 | 0.09 | Why? |
| Logistic Models | 3 | 2018 | 9089 | 0.09 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2019 | 10649 | 0.09 | Why? |
| Survivors | 1 | 2021 | 2619 | 0.09 | Why? |
| Europe | 4 | 2020 | 12702 | 0.09 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.09 | Why? |
| Critical Pathways | 1 | 2018 | 1587 | 0.09 | Why? |
| Lymphocytes | 1 | 2021 | 3056 | 0.09 | Why? |
| Seasons | 1 | 2020 | 4071 | 0.09 | Why? |
| Monocytes | 1 | 2020 | 2978 | 0.09 | Why? |
| Anti-HIV Agents | 1 | 2020 | 2209 | 0.09 | Why? |
| Malaria | 1 | 2017 | 1097 | 0.09 | Why? |
| Azoles | 2 | 2020 | 185 | 0.08 | Why? |
| Emigrants and Immigrants | 1 | 2016 | 888 | 0.08 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2021 | 4545 | 0.08 | Why? |
| Oxygen | 1 | 2021 | 3715 | 0.08 | Why? |
| Patient Isolation | 1 | 2021 | 3182 | 0.08 | Why? |
| Interferon Type I | 1 | 2020 | 2789 | 0.08 | Why? |
| Transcriptome | 1 | 2020 | 3466 | 0.08 | Why? |
| Outpatients | 1 | 2020 | 3417 | 0.08 | Why? |
| Microbiota | 1 | 2017 | 1240 | 0.08 | Why? |
| Clinical Protocols | 1 | 2018 | 2734 | 0.08 | Why? |
| Lopinavir | 1 | 2021 | 4308 | 0.08 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.08 | Why? |
| Survival Rate | 2 | 2020 | 9206 | 0.08 | Why? |
| Lung Diseases | 1 | 2020 | 2361 | 0.08 | Why? |
| Thrombocytopenia | 1 | 2019 | 2093 | 0.08 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.08 | Why? |
| Predictive Value of Tests | 2 | 2018 | 9537 | 0.08 | Why? |
| Blood Glucose | 1 | 2020 | 3642 | 0.08 | Why? |
| Renal Insufficiency, Chronic | 1 | 2020 | 2654 | 0.08 | Why? |
| Postoperative Complications | 1 | 2004 | 5861 | 0.08 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.07 | Why? |
| Genetic Predisposition to Disease | 1 | 2020 | 4027 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Monte Carlo Method | 2 | 2018 | 577 | 0.07 | Why? |
| Brain Ischemia | 1 | 2020 | 2813 | 0.07 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.07 | Why? |
| Drug Synergism | 1 | 2008 | 833 | 0.07 | Why? |
| Transients and Migrants | 1 | 2017 | 1468 | 0.07 | Why? |
| Serologic Tests | 1 | 2019 | 4359 | 0.07 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.07 | Why? |
| Respiratory System | 1 | 2017 | 3213 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.07 | Why? |
| Dose-Response Relationship, Drug | 3 | 2018 | 3776 | 0.07 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.07 | Why? |
| Parasitic Diseases | 1 | 2004 | 84 | 0.07 | Why? |
| Physicians | 2 | 2020 | 4214 | 0.06 | Why? |
| Lung | 3 | 2021 | 31049 | 0.06 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.06 | Why? |
| Liver Transplantation | 1 | 2018 | 2864 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.06 | Why? |
| Practice Patterns, Physicians' | 2 | 2019 | 4927 | 0.06 | Why? |
| Receptors, CCR6 | 1 | 2021 | 45 | 0.06 | Why? |
| Receptors, CCR4 | 1 | 2021 | 42 | 0.06 | Why? |
| Antibiotic Prophylaxis | 1 | 2004 | 399 | 0.06 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 11367 | 0.06 | Why? |
| Diabetes Mellitus | 2 | 2020 | 8207 | 0.06 | Why? |
| Bacteria | 1 | 2012 | 1897 | 0.06 | Why? |
| Thirst | 1 | 2020 | 20 | 0.05 | Why? |
| Ribavirin | 1 | 2008 | 1182 | 0.05 | Why? |
| Surgical Attire | 1 | 2020 | 36 | 0.05 | Why? |
| Oceania | 1 | 2020 | 91 | 0.05 | Why? |
| Remission Induction | 1 | 2004 | 950 | 0.05 | Why? |
| Aerosols | 1 | 2017 | 5393 | 0.05 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.05 | Why? |
| Magnetic Resonance Imaging | 1 | 2017 | 6551 | 0.05 | Why? |
| Escherichia coli | 2 | 2018 | 1547 | 0.05 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.05 | Why? |
| Hospitalization | 4 | 2020 | 54280 | 0.05 | Why? |
| Interferon-alpha | 1 | 2008 | 1442 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Communicable Diseases, Emerging | 1 | 2014 | 2523 | 0.05 | Why? |
| Animals | 6 | 2021 | 78931 | 0.05 | Why? |
| Fatal Outcome | 2 | 2020 | 3438 | 0.05 | Why? |
| Biomedical Research | 2 | 2017 | 5270 | 0.05 | Why? |
| Amphotericin B | 1 | 2020 | 256 | 0.05 | Why? |
| Sensitivity and Specificity | 2 | 2018 | 22971 | 0.05 | Why? |
| Piperacillin | 1 | 2018 | 63 | 0.05 | Why? |
| Pyomyositis | 1 | 2018 | 12 | 0.05 | Why? |
| Gas Gangrene | 1 | 2018 | 8 | 0.05 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.05 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.05 | Why? |
| Gloves, Protective | 1 | 2020 | 249 | 0.05 | Why? |
| Travel | 1 | 2017 | 7220 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Mupirocin | 1 | 2017 | 22 | 0.05 | Why? |
| South America | 1 | 2020 | 565 | 0.05 | Why? |
| Placebos | 1 | 2021 | 629 | 0.05 | Why? |
| Fluorescent Antibody Technique | 1 | 2021 | 835 | 0.04 | Why? |
| Levofloxacin | 1 | 2018 | 115 | 0.04 | Why? |
| Lung Diseases, Parasitic | 1 | 2017 | 17 | 0.04 | Why? |
| Dermatomycoses | 1 | 2018 | 55 | 0.04 | Why? |
| Heart Valves | 1 | 2017 | 52 | 0.04 | Why? |
| Schistosoma haematobium | 1 | 2017 | 35 | 0.04 | Why? |
| Blood Gas Analysis | 1 | 2021 | 893 | 0.04 | Why? |
| Gentamicins | 1 | 2017 | 76 | 0.04 | Why? |
| Ciprofloxacin | 1 | 2018 | 130 | 0.04 | Why? |
| Eye Protective Devices | 1 | 2020 | 245 | 0.04 | Why? |
| Glasgow Coma Scale | 1 | 2018 | 249 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Health Policy | 1 | 2017 | 6242 | 0.04 | Why? |
| Aminoglycosides | 1 | 2017 | 94 | 0.04 | Why? |
| Candida albicans | 1 | 2018 | 217 | 0.04 | Why? |
| United Kingdom | 1 | 2017 | 18046 | 0.04 | Why? |
| Hepatitis C | 1 | 2008 | 1514 | 0.04 | Why? |
| Plasmodium vivax | 1 | 2017 | 154 | 0.04 | Why? |
| Ceftriaxone | 1 | 2018 | 365 | 0.04 | Why? |
| Tertiary Care Centers | 3 | 2019 | 8248 | 0.04 | Why? |
| Arterial Pressure | 1 | 2018 | 208 | 0.04 | Why? |
| Allied Health Personnel | 1 | 2020 | 416 | 0.04 | Why? |
| Chlorhexidine | 1 | 2017 | 176 | 0.04 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.04 | Why? |
| Quinolones | 1 | 2017 | 167 | 0.04 | Why? |
| North America | 1 | 2020 | 1400 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Cause of Death | 2 | 2020 | 4823 | 0.04 | Why? |
| CD4 Lymphocyte Count | 1 | 2020 | 1517 | 0.04 | Why? |
| Combined Modality Therapy | 1 | 2004 | 3395 | 0.04 | Why? |
| Vaccination | 1 | 2020 | 19050 | 0.04 | Why? |
| beta-Lactams | 1 | 2017 | 210 | 0.04 | Why? |
| Patient Outcome Assessment | 1 | 2019 | 707 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2019 | 21571 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2018 | 961 | 0.03 | Why? |
| Epidemiological Monitoring | 2 | 2018 | 3493 | 0.03 | Why? |
| Statistics, Nonparametric | 1 | 2018 | 1008 | 0.03 | Why? |
| Pets | 1 | 2017 | 314 | 0.03 | Why? |
| Risk Assessment | 1 | 2018 | 25439 | 0.03 | Why? |
| Infectious Disease Medicine | 1 | 2017 | 311 | 0.03 | Why? |
| Travel Medicine | 1 | 2017 | 335 | 0.03 | Why? |
| Plasmodium falciparum | 1 | 2017 | 337 | 0.03 | Why? |
| DNA, Bacterial | 1 | 2018 | 835 | 0.03 | Why? |
| Platelet Count | 1 | 2019 | 1381 | 0.03 | Why? |
| Substance Abuse, Intravenous | 1 | 2018 | 411 | 0.03 | Why? |
| Eosinophilia | 1 | 2016 | 292 | 0.03 | Why? |
| Asia | 1 | 2020 | 2399 | 0.03 | Why? |
| Chemoprevention | 1 | 2017 | 585 | 0.03 | Why? |
| Immunoglobulins | 1 | 2018 | 811 | 0.03 | Why? |
| Flow Cytometry | 1 | 2021 | 2393 | 0.03 | Why? |
| Hot Temperature | 1 | 2020 | 1299 | 0.03 | Why? |
| Internal Medicine | 1 | 2018 | 557 | 0.03 | Why? |
| Organ Dysfunction Scores | 1 | 2018 | 1475 | 0.03 | Why? |
| Renal Replacement Therapy | 1 | 2020 | 1530 | 0.03 | Why? |
| Hospital Mortality | 3 | 2020 | 22087 | 0.03 | Why? |
| Lymphocyte Activation | 1 | 2021 | 2742 | 0.03 | Why? |
| Africa | 1 | 2020 | 2986 | 0.03 | Why? |
| Heart Valve Prosthesis Implantation | 1 | 2017 | 552 | 0.03 | Why? |
| Creatinine | 1 | 2017 | 1443 | 0.03 | Why? |
| Interferon-gamma | 1 | 2021 | 2711 | 0.03 | Why? |
| Personnel Staffing and Scheduling | 1 | 2020 | 1578 | 0.03 | Why? |
| Immune System | 1 | 2020 | 1479 | 0.03 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.02 | Why? |
| Headache | 1 | 2020 | 2257 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2019 | 4260 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.02 | Why? |
| Sex Distribution | 1 | 2016 | 2083 | 0.02 | Why? |
| Sentinel Surveillance | 1 | 2016 | 1093 | 0.02 | Why? |
| Regression Analysis | 1 | 2016 | 2484 | 0.02 | Why? |
| Tomography, X-Ray Computed | 3 | 2021 | 25144 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2020 | 3788 | 0.02 | Why? |
| Propensity Score | 1 | 2017 | 2690 | 0.02 | Why? |
| Hospitals | 2 | 2019 | 11793 | 0.02 | Why? |
| Software | 1 | 2020 | 2501 | 0.02 | Why? |
| Respiratory Protective Devices | 1 | 2020 | 1637 | 0.02 | Why? |
| Israel | 1 | 2017 | 2751 | 0.02 | Why? |
| Bayes Theorem | 1 | 2017 | 3237 | 0.02 | Why? |
| Delayed Diagnosis | 1 | 2017 | 1529 | 0.02 | Why? |
| Health Care Surveys | 1 | 2017 | 2942 | 0.02 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2018 | 3239 | 0.02 | Why? |
| Virus Diseases | 1 | 2004 | 3779 | 0.02 | Why? |
| Age Distribution | 1 | 2016 | 3567 | 0.02 | Why? |
| Turkey | 1 | 2017 | 3937 | 0.02 | Why? |
| Hospitals, University | 1 | 2017 | 4173 | 0.02 | Why? |
| Surgical Wound Infection | 1 | 2010 | 501 | 0.02 | Why? |
| Nurses | 1 | 2020 | 2285 | 0.02 | Why? |
| Hospitals, Public | 1 | 2010 | 774 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Kidney Transplantation | 1 | 2004 | 5397 | 0.02 | Why? |
| Polyethylene Glycols | 1 | 2008 | 574 | 0.02 | Why? |
| Ambulatory Care | 1 | 2021 | 4947 | 0.02 | Why? |
| Zoonoses | 1 | 2017 | 3034 | 0.02 | Why? |
| Electrocardiography | 1 | 2018 | 3957 | 0.02 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2008 | 952 | 0.02 | Why? |
| Internet | 1 | 2020 | 6204 | 0.01 | Why? |
| Adolescent | 3 | 2017 | 86841 | 0.01 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.01 | Why? |
| Demography | 1 | 2008 | 1660 | 0.01 | Why? |
| Intubation, Intratracheal | 1 | 2017 | 3962 | 0.01 | Why? |
| Models, Biological | 1 | 2018 | 4907 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 7868 | 0.01 | Why? |
| Young Adult | 3 | 2017 | 93724 | 0.01 | Why? |
| Guidelines as Topic | 1 | 2012 | 2844 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.01 | Why? |
| Recombinant Proteins | 1 | 2008 | 3786 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.01 | Why? |
| Masks | 1 | 2020 | 8528 | 0.01 | Why? |
| Child | 2 | 2017 | 70012 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
| Infant, Newborn | 1 | 2010 | 23105 | 0.01 | Why? |
| Infant | 1 | 2010 | 30274 | 0.01 | Why? |
| Child, Preschool | 1 | 2010 | 36283 | 0.00 | Why? |